A new outpatient clinic is enabling Memorial Sloan-Kettering's adult allogeneic bone marrow transplant service to enhance comfort and convenience for a rapidly growing patient population.
A new generation of microscopic particles for molecular imaging that may be adapted for tumor targeting and treatment in the clinic have been developed.
Memorial Sloan-Kettering investigators have found a way to restore innate immune defense in the intestines and enhance resistance to some drug-resistant bacteria.
Researchers have identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.
News@MSKCC provides journalists with news and information from Memorial Sloan-Kettering Cancer Center and is released six times a year.
For more information about these and other potential story ideas, contact Memorial Sloan-Kettering's Department of Public Affairs at: 212-639-3573 or at mediastaff@mskcc.org
